Does a Foreign Biotech Need a Local China Partner to File an IND with CDE?
One of the most common questions for foreign biotech companies considering clinical development in China is whether a local partner is legally required to file an Investigational New Drug (IND) application with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The answer has evolved significantly with China’s regulatory reforms since 2017, creating a more nuanced landscape than the binary “yes or no” that many assume.
This FAQ provides a definitive analysis of the legal requirements, practical considerations, and strategic options for foreign biotech companies regarding China IND filings. We examine the regulatory framework under the Provisions for Drug Registration (2020), the amendments introduced through the Drug Administration Law (2019), and the practical pathways available through wholly foreign-owned enterprises (WFOEs), Chinese partners, and regulatory agents.
The Direct Answer: Regulatory Requirements
Short answer: A foreign biotech company can file an IND with the CDE without a Chinese partner, but with important conditions.
Under the current regulatory framework, the entity filing the IND — the “applicant” or “sponsor” in Chinese regulatory terminology — must be a company legally registered in China. The foreign parent company incorporated in the United States, Europe, or any other jurisdiction cannot directly submit an IND application to the CDE. The IND must be submitted by a China-registered legal entity. However, this entity can be either:
- A Wholly Foreign-Owned Enterprise (WFOE) — a 100% foreign-invested company established in China by the foreign biotech company, which can serve as the IND sponsor without any Chinese partner equity participation
- A Joint Venture (JV) — a company with both foreign and Chinese ownership
- A Chinese company — hired as the local partner/sponsor of record, typically a local CRO acting as the legal sponsor
The key regulatory principle is that a WFOE can serve as the IND sponsor. This was not always the case — prior to 2015, foreign-invested enterprises faced significant restrictions on drug development activities. The Pharmaceutical Industry Negative List has been progressively liberalized, and as of 2026, a biotech WFOE faces no categorical bar on acting as an IND sponsor.
The Three Filing Models Compared
| Model | Entity Type | Chinese Partner Required? | Regulatory Control | Time to Establish | Typical Cost (Year 1) |
|---|---|---|---|---|---|
| WFOE Sponsor | Wholly foreign-owned enterprise | No (but may need regulatory agent) | Full — foreign parent controls all decisions | 3–6 months | USD 50,000–100,000 |
| JV Sponsor | Equity joint venture with Chinese partner | Yes — by definition | Shared — depends on equity split and JV agreement | 4–8 months | USD 80,000–200,000 |
| Local Partner as Sponsor of Record | Chinese CRO or partner company files as sponsor | Yes — the partner is the legal sponsor | Limited — the partner holds the IND and NDA | 1–3 months (contract negotiation) | USD 30,000–60,000 (service fees) |
The WFOE Pathway: What It Requires
For foreign biotech companies seeking maximum control over their China clinical development, the WFOE pathway is the preferred option. Here is what establishing and operating a WFOE IND sponsor requires:
Company Establishment Requirements
- Registered capital: Minimum requirements vary by industry park and local regulations, but a biotech WFOE should typically have RMB 5–20 million (USD 700,000–2,800,000) in registered capital to demonstrate substance and meet clinical trial financial guarantee requirements. The actual amount should be commensurate with the projected clinical development budget.
- Business scope: The WFOE’s business license must explicitly include “drug research and development” or “drug registration” in its approved scope. A generic “business consulting” or “technology services” scope is insufficient. The business scope should be carefully drafted by a China corporate lawyer to ensure it covers all intended IND sponsor activities.
- Registered address: The WFOE must have a physical registered address in China (a virtual office is generally not acceptable for drug development entities). Many biotech parks offer shared laboratory and office facilities that satisfy this requirement while reducing setup costs.
- Legal representative and directors: At least one legal representative must be appointed. This person can be a foreign national but must hold a valid Chinese work visa or residence permit. Most foreign biotech companies appoint a senior China-based executive as the legal representative.
Regulatory Agent Requirement
Even with a WFOE acting as the IND sponsor, foreign parent companies should designate a registered regulatory agent in China. Under the Provisions for Drug Registration, foreign drug manufacturers must have a China-based agent registered with the NMPA for: (a) imported drug registration and (b) post-approval lifecycle management. However, when the WFOE itself is the IND sponsor (rather than an imported drug application), the WFOE can serve as its own regulatory representative for the IND phase. Once the product transitions to an NDA for market authorization, an imported drug agent may be needed depending on the commercialization model.
Regulatory Comparison: WFOE Indirect Filing vs. Direct Foreign Submissions
It is important to understand that even with a WFOE, the filing is technically a “domestic” application by a Chinese-registered entity, not a direct foreign filing. This distinction affects the review pathway:
- WFOE-filed IND: Reviewed under the same standards as domestic Chinese biotech companies. The CDE review timeline is 60 working days, and the application uses the standard domestic application format and submission portal.
- Partner-filed IND (imported drug pathway): If filed as an imported drug by a Chinese partner, the review timeline is similar but the documentation requirements differ — particularly regarding overseas GMP certification and foreign clinical data.
- Direct filing by foreign parent: Not legally possible. The NMPA system does not accept applications from non-Chinese-registered entities.
When a Chinese Partner May Still Be Necessary
While a WFOE can serve as the IND sponsor, there are specific circumstances where a Chinese partner may still be necessary or highly advisable:
Human Genetic Resource (HGR) Compliance
Under China’s Human Genetic Resource Regulations, foreign entities (including WFOEs) cannot independently collect Chinese human genetic resources. For clinical trials involving the collection of Chinese subjects’ genetic material or genomic data, a Chinese research institution (hospital, university, or research institute) must be the applicant for HGR approval and serve as the primary custodian of the genetic resources. This means that even if the WFOE is the IND sponsor, a Chinese research institution partner is required for HGR compliance. The two roles — IND sponsor and HGR applicant — can be separate entities.
Clinical Trial Site Access
Clinical trials in China are conducted at NMPA-certified clinical trial sites (GCP hospitals). While the WFOE sponsor can contract directly with these hospitals, having a Chinese partner with established hospital relationships can significantly accelerate site selection, contract negotiation, and patient recruitment. Many foreign biotech companies find that a local CRO partner or strategic collaborator provides invaluable access to the top-tier clinical trial sites.
Commercialization Strategy
If the ultimate goal is to market the product in China, the commercialization model may necessitate a Chinese partner. A WFOE can hold the NDA (New Drug Application) registration certificate for innovative drugs, but the regulatory pathway becomes more complex for certain controlled substances, vaccines, and products requiring specialized distribution. Many foreign biotech companies use the WFOE for clinical development and then enter into distribution or co-marketing agreements with Chinese partners for commercialization.
Practical Steps: Setting Up Your IND Filing Entity
Option A: Establish a Biotech WFOE (Recommended for Companies with China Strategy)
- Engage a China corporate law firm specializing in life science company formation
- Select a location (biotech park) that aligns with your therapeutic area and offers favorable incentives
- Draft the company’s business scope to include drug R&D, clinical trial sponsorship, and drug registration
- Register the company with the Administration for Market Regulation (AMR) — 3–6 weeks
- Open corporate bank accounts and inject registered capital
- Apply for tax registration and HNTE eligibility assessment
- Hire or contract a qualified China regulatory affairs professional
- Establish IND preparation timeline aligned with CDE communication meeting schedule
Option B: Partner with a CRO as Sponsor of Record (Recommended for Single-Product Companies)
- Identify CROs with “sponsor of record” service capabilities (e.g., Tigermed, WuXi AppTec, Pharmaron, or international CROs with China operations)
- Negotiate a sponsor-of-record agreement that clearly defines regulatory responsibilities, liability allocation, and IP ownership
- Ensure the agreement includes provisions for CDE meeting participation, correspondence handling, and deficiency response management
- Verify the CRO’s regulatory track record with similar product categories and IND approval success rates
- Establish a joint steering committee with the CRO for IND preparation oversight
- Begin IND dossier preparation (the CRO will typically provide a regulatory pathway assessment and document gap analysis)
Cost-Benefit Analysis: WFOE vs. Partner Model
| Factor | WFOE Model | Partner Model |
|---|---|---|
| Upfront cost | Higher (USD 50K–100K setup) | Lower (USD 30K–60K contract fees) |
| Ongoing cost | Higher (USD 150K–300K/year overhead) | Variable (per-project fees) |
| Regulatory control | Full — all decisions made by foreign parent | Shared — partner has sponsor obligations |
| IP protection | Strong — assets held within wholly-owned entity | Requires careful contractual IP provisions |
| Speed to first IND | 6–9 months (incorporation + IND prep) | 3–6 months (contract + IND prep) |
| Scalability | High — platform for multiple pipeline products | Lower — renegotiate for each new product |
| Regulatory relationship value | Builds CDE relationship for the entity | Benefit accrues to partner, not the foreign company |
| Exit flexibility | Can wind down or sell the WFOE | Can terminate contract (may have penalties) |
Conclusion
A foreign biotech company does not need a Chinese joint venture partner per se to file an IND with the CDE. The establishment of a WFOE — a wholly foreign-owned enterprise — provides a legally sufficient vehicle for IND sponsorship without Chinese equity participation. This pathway gives foreign biotech companies full control over their clinical development strategy in China while complying with the requirement that the IND applicant be a China-registered legal entity.
However, the absence of a strict legal requirement for a Chinese partner does not mean that partnerships are unnecessary. The HGR regulations effectively require Chinese institutional partners for clinical trial sample collection, and practical considerations around site access, patient recruitment, and regulatory navigation make a local partner — whether a CRO, a clinical site network, or a strategic collaborator — highly valuable for successful IND filing and clinical execution.
For foreign biotech companies with a strategic commitment to the China market, establishing a WFOE and selectively engaging Chinese CROs and research institutions for specific functions offers the optimal balance of regulatory control, operational efficiency, and compliance management. For companies testing the China market with a single product, the sponsor-of-record model through a qualified CRO provides a faster, lower-cost entry point.
